Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10799686 | 0.87 | ACHE (0.40) | ACHE | |
| SCHEMBL19914968 | 0.87 | ACHE (0.40) | ACHE | |
| SCHEMBL19920828 | 0.87 | ACHE (0.40) | ACHE | |
| SCHEMBL880187 | 0.81 | TSHR (0.50) | ACHELMNATSHRCTSLCTSB | |
| SCHEMBL18516986 | 0.81 | TSHR (0.50) | ACHELMNATSHRCTSLCTSB | |
| SCHEMBL11537309 | 0.81 | SCN9A (0.40) | ALDH1A1ACHELMNATSHRCTSL | |
| SCHEMBL11537312 | 0.81 | SCN9A (0.40) | ALDH1A1ACHELMNATSHRCTSL | |
| SCHEMBL11537305 | 0.81 | SCN9A (0.40) | ALDH1A1ACHELMNATSHRCTSL | |
| SCHEMBL10803209 | 0.79 | PTPN1 (0.40) | LMNATSHR | |
| SCHEMBL11536019 | 0.77 | LMNA (0.37) | LMNATSHRCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057440-A1 | METHOD FOR SYNTHESIZING NOVEL COMPOUNDS DERIVED FROM 3-HYDROXY-CYCLOPENTYL ACETIC ACID | L'OREAL (FR) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057440-A1 | METHOD FOR SYNTHESIZING NOVEL COMPOUNDS DERIVED FROM 3-HYDROXY-CYCLOPENTYL ACETIC ACID | HSD17B12, FASN, AKR1C3 | ALDH1A1 39/4885ACHE 3938/4885LMNA 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.